One step closer to understanding and treating blood cancer
CTx have been researching the discovery and development of novel oncology drugs that target PRMT5 for the treatment of solid tumours and blood cancer and have just been recognised for their work on the PRMT5 program, with the Australian CRC Association’s (CRCA) Award for Excellence in Innovation.